- Home
- MTB vs ONC Comparison
MTB vs ONC Comparison
Compare MTB & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTB
- ONC
- Stock Information
- Founded
- MTB 1856
- ONC 2010
- Country
- MTB United States
- ONC Switzerland
- Employees
- MTB N/A
- ONC N/A
- Industry
- MTB Major Banks
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- MTB Finance
- ONC Health Care
- Exchange
- MTB Nasdaq
- ONC Nasdaq
- Market Cap
- MTB 28.6B
- ONC 26.9B
- IPO Year
- MTB N/A
- ONC N/A
- Fundamental
- Price
- MTB $202.86
- ONC $245.49
- Analyst Decision
- MTB Buy
- ONC Strong Buy
- Analyst Count
- MTB 20
- ONC 9
- Target Price
- MTB $208.20
- ONC $325.56
- AVG Volume (30 Days)
- MTB 1.2M
- ONC 367.8K
- Earning Date
- MTB 07-16-2025
- ONC 08-06-2025
- Dividend Yield
- MTB 2.67%
- ONC N/A
- EPS Growth
- MTB 1.00
- ONC N/A
- EPS
- MTB 14.94
- ONC N/A
- Revenue
- MTB $8,785,000,000.00
- ONC $4,175,868,000.00
- Revenue This Year
- MTB $11.90
- ONC $869.15
- Revenue Next Year
- MTB $4.16
- ONC $19.07
- P/E Ratio
- MTB $13.56
- ONC N/A
- Revenue Growth
- MTB 0.14
- ONC 51.16
- 52 Week Low
- MTB $145.82
- ONC $142.00
- 52 Week High
- MTB $225.70
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- MTB 75.80
- ONC N/A
- Support Level
- MTB $193.08
- ONC N/A
- Resistance Level
- MTB $193.21
- ONC N/A
- Average True Range (ATR)
- MTB 3.43
- ONC 0.00
- MACD
- MTB 1.53
- ONC 0.00
- Stochastic Oscillator
- MTB 96.18
- ONC 0.00
About MTB M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, Massachusetts, New Hampshire, Vermont, Maine, Connecticut, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.